Killing “Superbugs” With AI

🦠The next big thing. [Altucher Confidential] August 28, 2023 [WEBSITE]( | [UNSUBSCRIBE]( The next big thing isn't just around the corner — it's in Vegas. [Hero_Image] Killing “Superbugs” With AI New “WiFi Crypto” Token is Going NUTS! Only a handful of crypto investors know about this… But there’s a tiny, affordable device… That’s paid investors real crypto – every day, with zero work… Just for having a working WiFi connection! It sounds crazy, but it’s true… And [this 3:28 video]( explains everything. [Click here to view it NOW](. [Chris Campbell] CHRIS CAMPBELL Dear Reader, "I'm sorry, Dave. I'm afraid I can't do that." With those words, the antagonist AI of 2001: A Space Odyssey, HAL 9000, was etched into the memories of viewers… Showcasing a murderous machine turning against its human masters. Fast-forward more than half a century… HAL has made a triumphant return. But this time, the story is real, and HAL's purpose isn't to kill astronauts. It's to save our lives. Allow me to explain. Killing Superbugs With AI In February 2020, MIT researchers unveiled halicin, an antibiotic named after HAL 9000, that combats some of our deadliest bacterial foes. Consider… Traditional drug discovery is akin to deep-sea treasure hunting: laborious, expensive, and 99.99% of the time, you're left with trinkets rather than the elusive chest of gold. In short, it takes over a decade to traverse the vast oceans of scientific data, hoping to chance upon that one valuable discovery. Enter AI. With the help of AI, MIT navigators mapped over 6,000 compounds, and in record time, they discovered halicin. This gem now stands as a promising ally against the daunting specter of antibiotic-resistant 'superbugs'. One might say: Yeah. Yeah. I’ve heard this before. Indeed, medicine has tried to use AI in medicine since the mid-1960s. Stanford University, for instance, once flirted with DENDRAL, an early computer program to identify chemical compounds. It was a flop. Most people don’t realize that AI has been around since about the 1950s. These advances are 70 years in the making. But a lot has changed since. The technology is ready. And, right now, the small players are set to win the biggest. Urgent Note From James — Response Requested By Midnight Tomorrow [I just made a massive change to my Altucher’s Investment Network newsletter.]( This is one of the biggest changes to a newsletter in the history of our business… As far as I know, nothing like it has ever been done before. I’m adding 3 brand-new benefits to this all-new “Pro level” of Altucher’s Investment Network. And as one of my readers, I’d hate to see you left behind. That’s why – until MIDNIGHT tomorrow – [you’ll be able to upgrade your current subscription to this new “Pro level” by clicking here.]( [Seriously. Just click here now to see how to claim your upgrade.]( Little Pharma, Big Wins The real opportunities brewing are in a cohort called "little pharma" -- those underdog drug-makers, valued between $300 million to perhaps an overly-generous $5 billion. Picked right, their stocks are set to outpace the Big Pharma behemoths. What gives little pharma the edge? For starters, any tidbit of positive news -- be it a potential buyout, encouraging clinical trials, or a nod from regulators -- tends to rock the boat a lot more for these smaller firms. More importantly… Smaller players are also quicker to adopt and develop new tech -- like AI. And there's the crux: Small biotech teams and AI are reshaping drug discovery. AI doesn’t just cut the time for drug discovery, it can delve deep into our genetic makeup to craft tailor-made treatments (personalized medicine). Beyond that, it can refine drug designs, breathe new life into existing medications, and make clinical trials more efficient. It's this edge that will let the 'little guys' give the big pharma giants a run for their money. The synergy between AI and little pharma is only getting stronger. Our experts are keeping their eagle eyes trained for the most lucrative prospects ahead. In fact… Our colleague Ray Blanco, Paradigm’s in-house biotech maven, will no doubt be talking about his favorite biotech plays at our Paradigm Shift Summit in Vegas. Speaking of that. ONE DAY LEFT! As any seasoned investor knows, timing and insight are everything. If you want to get a leg up on these titanic shifts -- AI, crypto, biotech, energy, geopolitics, CBDCs, battery tech, and much more -- join us at the Paradigm Summit on October 3, 2023, in Vegas. The summit provides a unique way to see beyond the noise, and position yourself at the forefront of what's to come. (It’s also a great way to connect with fellow investors, industry experts, and all of our Paradigm gurus.) The next big thing isn't just around the corner — it's in Vegas. Consider this the last call. [Click here for all the details -- and to reserve your spot.]( Until next time, [Chris Campbell] Chris Campbell For Altucher Confidential Over 62 And Collect Social Security? Take Action Immediately! [James Altucher]( [If you’re over the age of 62 and currently collect Social Security, you need to prepare now](. Because Biden has given our country the worst inflation in decades – and many warn things will only get worse from here. Worse yet, the Social Security check you receive now may not keep pace with inflation… [Which is why, if you don’t act now, you could fall behind in the months ahead](. Is your retirement at immediate risk? [Click here now to get the simple, step-by-step actions to survive inflation](. [Paradigm]( ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](